SGAM
SUPN icon

Smith Group Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Smith Group Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-700
Closed -$22K – 395
2021
Q2 		$22K Hold
700
– – ﹤0.01% 226
2021
Q1 		$18K Sell
700
-31,368
-98% -$877K ﹤0.01% 224
2020
Q4 		$807K Sell
32,068
-5,730
-15% -$123K 0.05% 109
2020
Q3 		$788K Sell
37,798
-10
-0% -$227 0.04% 111
2020
Q2 		$898K Buy
+37,808
New +$835K 0.05% 106
2019
Q4 		– Sell
-15,627
Closed -$429K – 404
2019
Q3 		$429K Sell
15,627
-400
-2% -$11.9K 0.02% 156
2019
Q2 		$530K Sell
16,027
-339
-2% -$11.6K 0.02% 148
2019
Q1 		$573K Sell
16,366
-211
-1% -$7.85K 0.02% 157
2018
Q4 		$551K Sell
16,577
-4
-0% -$172 0.02% 188
2018
Q3 		$835K Sell
16,581
-42,940
-72% -$2.12M 0.02% 181
2018
Q2 		$3.56M Buy
59,521
+1,950
+3% +$101K 0.1% 98
2018
Q1 		$2.64M Buy
57,571
+12,009
+26% +$501K 0.09% 107
2017
Q4 		$1.82M Sell
45,562
-15,805
-26% -$625K 0.06% 151
2017
Q3 		$2.46M Sell
61,367
-10,762
-15% -$466K 0.08% 141
2017
Q2 		$3.11M Sell
72,129
-56,391
-44% -$2.01M 0.1% 133
2017
Q1 		$4.02M Sell
128,520
-3,451
-3% -$92.5K 0.12% 111
2016
Q4 		$3.33M Sell
131,971
-50,820
-28% -$1.14M 0.1% 119
2016
Q3 		$4.52M Sell
182,791
-20,822
-10% -$471K 0.13% 96
2016
Q2 		$4.15M Sell
203,613
-29,979
-13% -$532K 0.12% 97
2016
Q1 		$3.56M Buy
233,592
+232,380
+19,173% +$3.03M 0.11% 97
2015
Q4 		$16K Buy
+1,212
New +$18.7K ﹤0.01% 409

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Smith Group Asset Management's SUPN Position: Q3 2021 in Review

Smith Group Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2021, closing a stake of 700 shares — an estimated $22K sold.

Smith Group Asset Management first reported a position in SUPN in Q4 2015 and held it in 21 quarters. The position peaked at $4.52M in Q3 2016. 223 funds tracked by Wall St. Rank hold SUPN as of Q3 2021.

  • Smith Group Asset Management reported no remaining Supernus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Smith Group Asset Management sold 700 Supernus Pharmaceuticals shares in Q3 2021, an estimated $22K.
  • Smith Group Asset Management first reported a position in Supernus Pharmaceuticals in Q4 2015 and held it in 21 quarters.
  • Smith Group Asset Management's Supernus Pharmaceuticals position peaked at $4.52M in Q3 2016.
  • 223 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2021.

Based on Smith Group Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.